TW202106681A - 用於治療皮膚疾病之嘧啶jak抑制劑 - Google Patents

用於治療皮膚疾病之嘧啶jak抑制劑 Download PDF

Info

Publication number
TW202106681A
TW202106681A TW109113573A TW109113573A TW202106681A TW 202106681 A TW202106681 A TW 202106681A TW 109113573 A TW109113573 A TW 109113573A TW 109113573 A TW109113573 A TW 109113573A TW 202106681 A TW202106681 A TW 202106681A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
methyl
Prior art date
Application number
TW109113573A
Other languages
English (en)
Chinese (zh)
Inventor
菲利浦 A 格肯
建華 曹
Original Assignee
美商施萬生物製藥研發Ip有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商施萬生物製藥研發Ip有限責任公司 filed Critical 美商施萬生物製藥研發Ip有限責任公司
Publication of TW202106681A publication Critical patent/TW202106681A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109113573A 2019-04-24 2020-04-23 用於治療皮膚疾病之嘧啶jak抑制劑 TW202106681A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
US62/837,827 2019-04-24

Publications (1)

Publication Number Publication Date
TW202106681A true TW202106681A (zh) 2021-02-16

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113573A TW202106681A (zh) 2019-04-24 2020-04-23 用於治療皮膚疾病之嘧啶jak抑制劑

Country Status (11)

Country Link
US (1) US11439641B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959213B1 (cg-RX-API-DMAC7.html)
JP (1) JP7482152B2 (cg-RX-API-DMAC7.html)
AR (1) AR118767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3135388A1 (cg-RX-API-DMAC7.html)
ES (1) ES2994097T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067909T2 (cg-RX-API-DMAC7.html)
PL (1) PL3959213T3 (cg-RX-API-DMAC7.html)
TW (1) TW202106681A (cg-RX-API-DMAC7.html)
WO (1) WO2020219640A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
AU2022270072A1 (en) 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
TWI740288B (zh) 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN115925705B (zh) 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药(上海)有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药(杭州)有限公司 一类jak激酶抑制剂及其制备和应用

Also Published As

Publication number Publication date
EP3959213C0 (en) 2024-06-05
US20200338073A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
CA3135388A1 (en) 2020-10-29
AR118767A1 (es) 2021-10-27
JP7482152B2 (ja) 2024-05-13
US11439641B2 (en) 2022-09-13
EP3959213A1 (en) 2022-03-02
EP3959213B1 (en) 2024-06-05
WO2020219640A1 (en) 2020-10-29
PL3959213T3 (pl) 2024-11-04
HRP20241053T1 (hr) 2024-11-08
ES2994097T3 (en) 2025-01-17
HUE067909T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
JP7470713B2 (ja) Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
EP3959213B1 (en) Pyrimidine jak inhibitors for the treatment of skin diseases
JP7623301B2 (ja) Il-17調節剤としてのイミダゾピリジン誘導体
JP6881879B2 (ja) Jakキナーゼ阻害剤としてのピリミジン化合物
JP7098716B2 (ja) Jakキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
US10766906B2 (en) Fused hexacyclic imidazole derivatives as modulators of TNF activity
JP7218364B2 (ja) Jakキナーゼ阻害剤としてのピリミジン化合物
JP2021534244A (ja) ピロロピリミジンitk阻害剤
JP2011514909A (ja) Jak阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
JP2022518741A (ja) JAKキナーゼ阻害剤としてのイミダゾ[1,5-a]ピリジン、1,2,4-トリアゾロ[4,3-a]ピリジンおよびイミダゾ[1,5-a]ピラジン
JP2019512534A (ja) Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
CA2823935A1 (en) Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
OA19911A (en) Pyrimidine compound as JAK kinase inhibitor.
HK40029509B (en) Pyrimidine compound as jak kinase inhibitor
HK40029509A (en) Pyrimidine compound as jak kinase inhibitor
HK1172621A (en) Pyrrolo[2,3-d] pyrimidine compounds